Phaseline

Companies › CG Oncology

CG Oncology: clinical trials, targets and expected readouts

1 active drug program in 3 registered trials: 2 Phase 3, 1 Phase 2; Oncology; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Cretostimogene Grenadenorepvec
Engineered oncolytic adenovirus expressing GM-CSF
–Phase 3Non Muscle Invasive Bladder Cancer; High-Risk Non-Muscle-Invasive Bladder CancerNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06111235Cretostimogene GrenadenorepvecPhase 3Non Muscle Invasive Bladder CancerOncologyNov 2026
NCT06567743Cretostimogene GrenadenorepvecPhase 2High-Risk Non-Muscle-Invasive Bladder CancerOncologyMar 2027
NCT04452591Cretostimogene GrenadenorepvecPhase 3Non Muscle Invasive Bladder CancerOncologyJun 2030

From the company's SEC filings

Cash and short-term investments of $984m on 2026-09-30; operating cash outflow about $203m a year; runway about 58 months at that burn, to Aug 2031; 3 of 3 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 8 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Suzhou Immunofoco Biotechnology Lakefront Biotherapeutics GT Medical Technologies Biofrontera Delcath Systems

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.